Despite saying it supported lower drug prices, Eli Lilly spent tens of millions of dollars lobbying over the last decade — including fighting against legislation to reduce the price of insulin and other life-saving prescription drugs.
Now, a group of shareholders have filed a proposal that would make Eli Lilly be fully transparent about its lobbying activities and reveal whether its behind-closed-doors lobbying matches its public statements.
This lobbying transparency proposal will be voted on at Eli Lilly’s annual shareholder meeting this May.
Add your name to our petition to show Eli Lilly shareholders that there’s overwhelming support for their corporate lobbying transparency proposal: